Findx
EnglishEnglish
Dansk Dansk

Active Biotech AB (publ) stock analysis ACTI.SE

Active Biotech AB (publ) develops immunomodulatory therapeutics, focusing its primary business on internally owned small-molecule drug candidates for hematological malignancies and inflammatory eye diseases. The lead molecule, tasquinimod, is in clinical development for myelofibrosis and has also advanced in studies for multiple myeloma. A second owned program, laquinimod, is being developed as a topical ophthalmic formulation for non-infectious uveitis, with completed Phase I clinical and biodistribution studies. The company also holds a partnered immunotherapy project, naptumomab estafenatox (naptumomab), in clinical trials for advanced solid tumors under a license to NeoTX Therapeutics.

Beyond its core development pipeline, the business model emphasizes advancing programs into clinical phases internally and then engaging external partners or licensees to carry them further. The company has sharpened its commercial strategy for laquinimod by seeking an ophthalmology-specialized partner to support its continued development. Intellectual property protection is maintained for key formulations and indications, including patents for tasquinimod formulations and ocular delivery of laquinimod. Regulatory interactions include feedback from authorities such as the US FDA on study protocols, particularly for tasquinimod.

Active Biotech is based in Lund, Sweden and develops therapeutics for specialist indications with unmet medical needs, particularly rare or niche diseases. The company engages in early to mid-stage clinical development, conducting safety, biodistribution and proof-of-concept studies. It leverages academic and institutional collaborations for research and trials. Commercialization is expected through partnerships, rather than full internal commercialization.

Healthcare · Biotechnology · Biotechnology · Sweden
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Not yet
A short-term bounce, not yet a trend change. Price is above SMA 20, but the moving averages are still falling, so being above them reflects a bounce inside a downtrend rather than a reversal. Wait for the averages to flatten and turn up before entering.
Trend
Trend: Trend broken
Trend broken. Two or more consecutive closes below SMA 50 signal that the medium-term trend has flipped. Exiting here is the rule rather than the exception.
‹
›

Click to see warnings

Neg. values
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: Q2 FY2026 / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: Q2 FY2026 (); filed
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: , 1 analyst

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Score calculated; High confidence; TTM used
Business Momentum: Unavailable; Not enough evidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Business Momentum score unavailable because too little of the model could be assessed. Missing: Latest surprise, Estimate revisions, Profitability, Revenue.
  • Limited confidence for Strength by model design: diluted EPS stood in for normalized EPS.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx
  • FCF margin: approved fallback

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
SEK N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-67.63%
Market Cap:SEK 103.99 M
EUR 9.45 M

Valuation basis

Analyst price target
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :

EPS Estimates

:
N/A
:
N/A
:
N/A

About Active Biotech AB (publ)

Description, revenue sources, strengths and weaknesses

DESCRIPTION

Active Biotech AB (publ) develops immunomodulatory therapeutics, focusing its primary business on internally owned small-molecule drug candidates for hematological malignancies and inflammatory eye diseases. The lead molecule, tasquinimod, is in clinical development for myelofibrosis and has also advanced in studies for multiple myeloma. A second owned program, laquinimod, is being developed as a topical ophthalmic formulation for non-infectious uveitis, with completed Phase I clinical and biodistribution studies. The company also holds a partnered immunotherapy project, naptumomab estafenatox (naptumomab), in clinical trials for advanced solid tumors under a license to NeoTX Therapeutics.

Beyond its core development pipeline, the business model emphasizes advancing programs into clinical phases internally and then engaging external partners or licensees to carry them further. The company has sharpened its commercial strategy for laquinimod by seeking an ophthalmology-specialized partner to support its continued development. Intellectual property protection is maintained for key formulations and indications, including patents for tasquinimod formulations and ocular delivery of laquinimod. Regulatory interactions include feedback from authorities such as the US FDA on study protocols, particularly for tasquinimod.

Active Biotech is based in Lund, Sweden and develops therapeutics for specialist indications with unmet medical needs, particularly rare or niche diseases. The company engages in early to mid-stage clinical development, conducting safety, biodistribution and proof-of-concept studies. It leverages academic and institutional collaborations for research and trials. Commercialization is expected through partnerships, rather than full internal commercialization.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.